Rosemont Pharmaceuticals Announced on November 16, 2026

Rosemont Pharmaceuticals announced on Monday a definitive agreement to acquire Aytu BioPharma for $2.70 per share in an all-cash transaction. The deal aims to expand Rosemont’s US market presence within the specialty pharmaceutical sector.

The acquisition focuses on integrating Aytu BioPharma’s existing portfolio of central nervous system (CNS) treatments, specifically targeting ADHD and Major Depressive Disorder (MDD).

The inclusion of ADHD medications within the portfolio indicates a strategic focus on pediatric and adult neurodevelopmental care. Rosemont, historically specialized in oral liquid medicines for patients with difficulty swallowing, intends to use its manufacturing expertise to support the distribution and development of these complex specialty medicines.

  • Targeted Therapy: The acquisition brings new treatments for depression and ADHD into the Rosemont portfolio.
  • Specialized Delivery: Rosemont’s expertise in liquid formulations may provide alternative ways to administer these CNS medications for patients who cannot swallow standard tablets.
  • Transition Stability: The companies have confirmed that operations will remain independent until the transaction closes in late December 2026.

Rosemont Pharmaceuticals is backed by the private equity firm Inflexion. Inflexion has $21bn of assets under management and established a dedicated New York City office in 2025. Alok Sonig, CEO of Rosemont, stated: “The proposed acquisition of Aytu marks an important step in Rosemont’s US growth strategy.”

Josh Disbrow, CEO of Aytu BioPharma, noted: “This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve.”

Metric Details
Acquisition Price $2.70 per share (Cash)
Key Therapeutic Areas Major Depressive Disorder (MDD), ADHD
Anticipated Closing Late December 2026

Always consult a healthcare professional before altering a medication regimen. Patients should review this information carefully with their provider.

The merger remains subject to the satisfaction or waiver of the conditions in the tender offer. Rosemont intends to file a Schedule TO—a document detailing the tender offer—with the U.S. Securities and Exchange Commission (SEC) within 10 business days. Aytu will concurrently file a Schedule 14D-9, providing its formal position on the offer. Until the transaction concludes, both companies will continue to operate as separate entities.

Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Germany Prepares for 2027 IHF Men’s World Championship With 35-Player Roster